{"id":"remternetug-sc","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, remternetug prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on the immune system and allowing it to attack cancer cells more effectively.","oneSentence":"Remternetug is a monoclonal antibody that targets the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:25.011Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT07346495","phase":"PHASE1","title":"A Study of Remternetug (LY3372993) in Healthy Chinese Participants","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-01-31","conditions":"Healthy","enrollment":24},{"nctId":"NCT05552157","phase":"PHASE2, PHASE3","title":"A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-22","conditions":"Alzheimers Disease, Dementia, Alzheimers Disease, Familial","enrollment":280},{"nctId":"NCT07056309","phase":"PHASE1","title":"A Study of Remternetug (LY3372993) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2025-06-24","conditions":"Healthy","enrollment":72},{"nctId":"NCT06653153","phase":"PHASE3","title":"A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-10-24","conditions":"Alzheimer's Disease","enrollment":1400},{"nctId":"NCT05463731","phase":"PHASE3","title":"A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-08-01","conditions":"Alzheimer's Disease","enrollment":1667}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY3372993"],"phase":"phase_3","status":"active","brandName":"Remternetug (SC)","genericName":"Remternetug (SC)","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Remternetug is a monoclonal antibody that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}